Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that preferentially blocks α1A receptors found in the prostate and bladder neck, facilitating smooth muscle relaxation to improve urine flow.
## Primary Indications
* Signs and symptoms of Benign Prostatic Hyperplasia (BPH).
* Off-label: Medical expulsive therapy for distal ureteral calculi (urolithiasis).
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day.
* **Maximum Dose:** 0.8 mg daily if no response after 2–4 weeks at 0.4 mg.
* **Urolithiasis (Off-label):** 0.4 mg once daily for up to 4 weeks.
## Pediatric Dosing
* **Not indicated/Not established.** Safety and efficacy have not been established in pediatric patients.
## Dose Adjustments
* **Renal Impairment:** No initial dose adjustment required. Caution in severe impairment (CrCl <10 mL/min).
* **Hepatic Impairment:** Not recommended in severe hepatic impairment (Child-Pugh Class C). No adjustment typically required for mild-to-moderate impairment.
* **CYP3A4 Inhibitors:** If initiated with strong inhibitors (e.g., ketoconazole, ritonavir), dose reduction or temporary suspension may be required.
## Contraindications
* Known hypersensitivity to tamsulosin or any component of the formulation.
* History of angioedema.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde ejaculation), rhinitis.
* **Serious:** Orthostatic hypotension (rare, but increased risk during initiation), syncope, severe allergic reactions (angioedema, urticaria).
* **Intraoperative:** Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.
## Key Drug Interactions
* **PDE-5 Inhibitors:** Concomitant use (e.g., sildenafil, tadalafil) increases the risk of symptomatic hypotension. Observe caution.
* **Strong CYP3A4/2D6 Inhibitors:** May significantly increase plasma concentrations of tamsulosin.
* **Antihypertensives:** Potential additive hypotensive effects.
## Monitoring
* Baseline and periodic assessment of BPH symptoms (e.g., IPSS score).
* Monitor blood pressure periodically, especially in patients on concurrent antihypertensives.
* Assess for orthostatic symptoms (dizziness, lightheadedness) upon initiation or dose escalation.
## Clinical Pearls
* **Administration:** Always administer 30 minutes after the same meal each day to ensure consistent bioavailability; fasting absorption is significantly higher and increases side effect risk.
* **Cataract Surgery:** Patients should inform their ophthalmologist of tamsulosin use, as the drug can cause IFIS, which complicates cataract surgery.
* **Orthostasis:** Advise patients to rise slowly from a sitting or lying position, especially when starting therapy.
* **Sulfa Allergy:** While generally considered low risk, tamsulosin contains a sulfonamide moiety; monitor patients with severe sulfonamide allergies for hypersensitivity reactions.
***
**Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and local protocols vary. Please verify current prescribing information through official FDA/EMA drug labels or authoritative clinical databases before prescribing or administering medication.
